Infections and Infectious Diseases | New Developments | CHINA

Sanyou Biopharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Shanghai Henlius Biotech Says Entered Cooperation Agreement With Sanyou Biopharmaceuticals & Shanghai Zj Bio-Tech

Lead Product(s): Antibody drug conjugate

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Shanghai Henlius Biotech

Deal Size: $3.5 million Upfront Cash: Undisclosed

Deal Type: Agreement May 06, 2020

Details:

Agreement aims to develop fully human antibody drug for covid-19 for monotherapy or combination treatment of covid-19.

Shanghai Junshi Biosciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Junshi, Eli Lilly Agree to Co-develop JS016 Antibodies Against COVID-19

Lead Product(s): JS016

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Eli Lilly

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement May 04, 2020

Details:

Junshi Biosciences and Lilly aim to submit an IND application and initiate clinical studies in the U.S. in the second quarter of the year.

Sino Biological

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

GeoVax and Sino Biological Establish Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development

Lead Product(s): Recombinant proteins

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: GeoVax Labs

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement April 30, 2020

Details:

Sino Biological will provide key bioreagents such as recombinant proteins, antibodies and detection kits for use in COVID-19 vaccine development underway at GeoVax.

BeiGene

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

BeiGene Launching Brukinsa Trial In Later-Stage COVID-19 Patients

Lead Product(s): Zanubrutinib

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 16, 2020

Details:

BeiGene has submitted a phase-2 randomized trial to the Food and Drug Administration that plans to enroll 42 U.S. patients.

Mabpharm

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Sorrento Collaborates with Mabpharm On Development and Commercialization of Ace-Mab™ to Potentially Treat Covid-19

Lead Product(s): ACE-MAB

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Sorrento Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement March 24, 2020

Details:

Sorrento has been granted an exclusive license to develop and commercialize the ACE-MAB product candidate in the North American and European markets.

Zhejiang Hisun Pharmaceutical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Zhejiang Hisun Pharmaceutical Favipiravir Works - Preliminary Clinical Studies Suggest Positive Effects on COVID-19 Patients

Lead Product(s): Favipiravir

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 19, 2020

Details:

Favipiravir alleviated the pneumonia symptom of COVID-19 patients with high tolerance and few adverse reactions, potentially through a mechanism that can quickly eliminate the coronaviruses.

Sihuan Pharmaceutical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Sihuan Announces Clinical Research of Favipiravir, Co-Developed

Lead Product(s): Favipiravir

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 02, 2020

Details:

The Trials are random, parallel dose exploration studies with three dosage groups (high, middle and low dosage) to explore the best treatment regimen of Favipiravir for COVID-19 patients.

WuXi Biologics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

WuXi Biologics and Vir Biotechnology Announce Collaboration for Global Development of Antibodies to Treat COVID-19

Lead Product(s): Human monoclonal antibodies

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Vir Biotechnology

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration February 25, 2020

Details:

Under the terms of the agreement, the companies will work together on the clinical development, manufacturing, and commercialization of Vir's proprietary antibodies.

Zhejiang Hisun Pharmaceutical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

China approves first anti-viral drug against coronavirus Covid-19

Lead Product(s): Favipiravir

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 18, 2020

Details:

Fapilavir allegedly demonstrated efficacy with minor side effects in an ongoing 70-patient clinical trial in Shenzhen, Guangdong province. The drug’s generic version received the approval.

Clover Biopharmaceutical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Clover Successfully Produced 2019-nCoV Subunit Vaccine Candidate

Lead Product(s): S-Trimer

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Undisclosed Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 10, 2020

Details:

Clover is the first company in the world to disclose a 2019-nCoV vaccine candidate that can successfully be recognized by antibodies produced by previously-infected patients.

Find

Find Novel Drugs for Infections and Infectious Diseases under Development in CHINA

China

A collaboration with SCORR Marketing

Product Type

Companies

Sanyou Biopharmaceuticals

Shanghai Henlius Biotech Says Entered Cooperation Agreement With Sanyou Biopharmaceuticals & Shanghai Zj Bio-Tech

Shanghai Junshi Biosciences

Junshi, Eli Lilly Agree to Co-develop JS016 Antibodies Against COVID-19

Sino Biological

GeoVax and Sino Biological Establish Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development

BeiGene

BeiGene Launching Brukinsa Trial In Later-Stage COVID-19 Patients

Mabpharm

Sorrento Collaborates with Mabpharm On Development and Commercialization of Ace-Mab™ to Potentially Treat Covid-19

Zhejiang Hisun Pharmaceutical

Zhejiang Hisun Pharmaceutical Favipiravir Works - Preliminary Clinical Studies Suggest Positive Effects on COVID-19 Patients

Sihuan Pharmaceutical

Sihuan Announces Clinical Research of Favipiravir, Co-Developed

WuXi Biologics

WuXi Biologics and Vir Biotechnology Announce Collaboration for Global Development of Antibodies to Treat COVID-19

Zhejiang Hisun Pharmaceutical

China approves first anti-viral drug against coronavirus Covid-19

Clover Biopharmaceutical

Clover Successfully Produced 2019-nCoV Subunit Vaccine Candidate